Chinese vaccine-maker CanSino Biologics Inc. is planning to list on Shanghai's Starboard Exchange, Bloomberg News reported.
The Tianjin-based company, which went public on the Hong Kong Stock Exchange in March, is planning to issue up to 24.8 million A shares on Starboard.
Starboard is seen as China's answer to the Hong Kong Stock Excahnge, which relaxed rules for pre-revenue companies in 2018 to list on the exchange. Starboard, which is hosted by the Shanghai Stock Exchange, is the first board in China to enable pre-profit, high-tech startups and companies with dual-class shareholding structures to conduct IPOs and be traded publicly.
CanSino — whose Ebola vaccine Ad5-EBOV was approved in China for emergency use and for national stockpiling purposes — said in March that it was planning to release two vaccines for a deadly brain and spinal cord infection called meningitis in the Asian country.